Enzymatica AB (publ) (STO: ENZY)

Market Cap	375.44M
Revenue (ttm)	44.25M
Net Income (ttm)	-53.96M
Shares Out	215.77M
EPS (ttm)	-0.31
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	46,774
Open	1.790
Previous Close	1.780
Day's Range	1.700 - 1.800
52-Week Range	1.650 - 4.190
Beta	-0.01
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 7, 2024

About Enzymatica AB

Enzymatica AB (publ), a life science company, develops and sells products that treat and alleviate infections and symptoms in the upper respiratory tract. The company’s product includes ColdZyme, a mouth spray to treat and alleviate cold and flu symptoms. It also provides enzyme formulations for skin care. The company offers its products through contract organizations and partner agreements with distributors who sell the products under the ViruProtect, STADAProtect, and Bisolviral brand names. Enzymatica AB (publ) was incorporated in 2007 and i...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2007
• Employees: 18
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: ENZY

Financial Performance

In 2023, Enzymatica AB's revenue was 50.90 million, an increase of 4.00% compared to the previous year's 48.95 million. Losses were -49.73 million, -27.57% less than in 2022.